(Q50560029)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24145815%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

title

Use of exenatide and liraglutide in Denmark: a drug utilization study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24145815%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24145815%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Jesper Hallas

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24145815%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Filip K Knop

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24145815%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

author name string

Bine Kjøller Bjerregaard

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24145815%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Michael Due Larsen

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24145815%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Kasper Søltoft Larsen

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24145815%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Søren Ilsøe Moreno

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24145815%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

publication date

22 October 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24145815%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Clinical Pharmacology

28 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24145815%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

volume

70

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24145815%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24145815%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

page(s)

205-214

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24145815%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00228-013-1595-4

28 February 2020

exact match

0 references

cites work

The Danish National Diabetes Register: trends in incidence, prevalence and mortality

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1595-4

Rising prevalence of diabetes: evidence from a Danish pharmaco-epidemiological database

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1595-4

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1595-4

Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1595-4

Cardiovascular outcomes in trials of oral diabetes medications: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1595-4

Metformin use and mortality among patients with diabetes and atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1595-4

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1595-4

Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1595-4

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1595-4

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1595-4

GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1595-4

Epidemiology. When an entire country is a cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1595-4

Danish population-based registers for public health and health-related welfare research: introduction to the supplement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1595-4

The Danish National Prescription Registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1595-4

The Danish Civil Registration System.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1595-4

Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1595-4

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1595-4

Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled tr

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1595-4

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1595-4

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1595-4

Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1595-4

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1595-4

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1595-4

The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1595-4

Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1595-4

The Danish prescription registries.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24145815

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24145815

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24145815